Vyome Biosciences has raised $8 million in Series B funding. Sabre Partners led the round with participation from return backers Kalaari Capital and Aarin Capital. Based in India, Vyome is focused on treating skin conditions such as dandruff and skin fungal infections.
DELHI, August 12, 2014 /PRNewswire/ –Vyome Biosciences, an innovation-driven dermatology company focused on developing novel and breakthrough treatments for hard to treat and refractory skin conditions such as persistent dandruff and skin fungal infections, resistant acne and other skin bacterial infections, today announced that it has closed Series B financing of US$ 8 million led by Sabre Partners, with existing Series A investors Kalaari Capital and Aarin Capital also co-investing.
Vyome was co-founded by Dr. Shiladitya Sengupta, co-chair at the Center for Regenerative Therapeutics at Brigham & Women’s Hospital in Boston and assistant professor of Medicine at Harvard Medical School, Dr. Rajesh Gokhale, director of the Institute of Genomics & Integrative Biology in Delhi, N. Venkat, who earlier worked as CEO of Emami and President of Shantha Biotechnics and Rajiv Mantri, Executive Director, Navam Capital.
Vyome is pioneering the development of a deep pipeline of molecules, including ‘first in class’ Molecular Replacement Therapeutics, MRT™ for killing dandruff-causing fungus, new antibiotics using Dual Action Rational Therapeutics, DART™ Technology that kill resistant acne-causing bacteria, and has developed a robust global patent portfolio. Vyome recently successfully completed clinical studies on VB001 and VB2421 for mild to moderate dandruff.
Speaking on the occasion, N. Venkat, Co-Founder and CEO of Vyome said, “This financing is a major landmark in Vyome’s journey to translate cutting-edge science into differentiated products and innovative commercialization strategies, and gives the company substantial firepower to drive the completion of critical milestones of USFDA filings and Phase 1 & Phase 2 clinical research for some of its lead compounds and other development and commercialization efforts of its Rx and OTC pipeline.”
“Four years ago, Vyome set out to do what had never been done in India; that is to create innovation-based products for global markets out of India. Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. This financing is another important milestone in Vyome’s pioneering effort to deliver innovative solutions in dermatology,” said Dr. Raghunath Mashelkar, Padma Vibhushan awardee and Chairman of Vyome.
“We are delighted to partner with a world-class team that is applying science and critical understanding of unmet needs to develop unique platform technologies and products for the $20 billion global dermatology market,” said Rajiv Maliwal, Founder and Managing Partner, Sabre Partners.
About Sabre Partners
Sabre Partners, founded by a group of professionals led by Rajiv Maliwal, has invested over $300 million in India and one of their best known investments was in the restructuring of Centurion Bank, which they subsequently sold to HDFC Bank. Sabre also has an infrastructure fund and a healthcare focused venture capital fund called ‘Spring Healthcare’, through which this investment in Vyome was made and through which Sabre has built a high quality healthcare and life sciences portfolio over the past 4 years.
About Vyome Biosciences Private Limited
Vyome is an India based biopharmaceutical company focused on the development of novel therapeutics for hard to treat and refractory dermatology diseases. Vyome has successfully completed clinical research on two products and two lead compounds are in preclinical stage of USFDA program. Vyome has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses.